Natera, Inc. research snapshot
NTRA AI stock analysis currently reads Natera, Inc. as a fast-growing molecular diagnostics company with strong Signatera oncology adoption, improving gross margin, positive quarterly cash inflow, and a demanding valuation while GAAP losses persist. At the July 11, 2026 data cutoff, the latest available July 8 close was $272.82 and implied market capitalization was about $39.07 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$272.82
Market cap
$39.07 billion
AI score
64 / 100
Rating
High-growth diagnostics platform, valuation-sensitive
Trend status
Revenue growth and technical references are constructive, while profitability and reimbursement risk remain material
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Natera sells molecular testing services across oncology, organ health, and women’s health, with Signatera personalized ctDNA monitoring as a central growth engine. | High |
| Moat | Clinical evidence, lab operations, bioinformatics, physician workflows, payer evidence, and accumulated test data can reinforce adoption, but the moat depends on sustained clinical utility and coverage. | Medium |
| Management | CEO Steve Chapman’s team has delivered rapid revenue growth and raised 2026 revenue guidance, but the next test is converting scale into durable profitability without excessive dilution or spending. | Medium-high |
| Financial trend | FY2025 revenue grew 35.9% to $2.306 billion. Q1 2026 revenue grew 38.8% to $696.6 million and gross margin reached 64.7%, but Q1 GAAP net loss was $85.1 million. | High |
| Valuation | At the latest $272.82 close, NTRA was valued at about $39.07 billion, roughly 15.6x trailing revenue. A GAAP P/E is not meaningful because the company remains loss-making. | High |
| Technical trend | July 9 technical references were broadly constructive, with buy signals across most moving averages and indicators, but price sits near a volatile 52-week high area. | Medium |
| Risk level | Risk is high because the thesis relies on reimbursement, clinical adoption, oncology execution, test pricing, competition, litigation, and a premium revenue multiple. | High |
| AI confidence | Reported facts and calculations are well supported. Exact share-price outcomes are not reliably predictable, particularly for a high-multiple healthcare growth stock. | High data confidence |
| Investment certainty | Medium-low certainty. The operating trajectory is strong, but an investment case needs continued revenue growth, improving operating leverage, and resilient reimbursement. | Medium-low |
NTRA AI stock forecast
The NTRA AI stock forecast uses operating and valuation scenarios around the latest $272.82 close, rather than a P/E target. Natera reported a trailing GAAP loss, so a mechanical EPS multiple produces non-economic negative values and is not a useful valuation anchor. The scenario ranges below are conditional, not price promises.
$300 to $330
More likely if 2026 revenue reaches or exceeds the $2.74 billion to $2.82 billion guidance range, Signatera and oncology volumes maintain strong growth, gross margin holds near guidance, cash inflow remains positive, and payers continue to broaden access.
$225 to $285
More likely if revenue growth remains high but investors apply a lower revenue multiple while Natera continues spending on commercial expansion, clinical evidence, and research.
$150 to $210
More likely if reimbursement or average selling prices weaken, oncology adoption slows, competitors gain share, losses persist longer than expected, or the premium valuation compresses.
NTRA AI technical analysis
NTRA AI technical analysis is constructive but volatile at the July 11, 2026 cutoff. Investing.com reported a Strong Buy indicator summary on July 9, with RSI near neutral and buy signals across most moving averages. The latest available July 8 close of $272.82 was below the recent $288.04 52-week high, so confirmation around resistance still matters.
| Level | Value | Why it matters |
|---|---|---|
| Latest available close | $272.82 | StockAnalysis market-cap snapshot at the July 8, 2026 close. Markets were closed by the July 11 research cutoff. |
| Near support | $270 | The July 8 daily range low was $269.66. A sustained close below this area would weaken the near-term setup. |
| Secondary support | $262 to $264 | Investing.com listed the 100-day simple and exponential moving averages near $262.47 and $263.82 on July 9. |
| Moving averages | $274 to $280 short-term, $240 to $247 long-term | July 9 references placed the 50-day simple average near $277.56 and the 200-day simple and exponential averages near $239.90 and $246.96. |
| Resistance | $280 to $288 | The short moving-average band and the $288.04 52-week high from the July 8 snapshot define the first resistance area. |
| Momentum | Constructive, not overbought | Investing.com listed RSI(14) at 54.325, MACD as Buy, and StochRSI as Overbought on July 9, which argues for disciplined entries rather than chasing. |
| Volume | Monitor against earnings and reimbursement news | NTRA can reprice sharply around test volumes, guidance, payer decisions, clinical data, and litigation developments. |
| Volatility | Elevated | Investing.com listed ATR(14) at 4.1403 on July 9. Use position sizing that recognizes healthcare growth-stock event risk. |
| Invalidation | Close below $270, then $262 | A break below the latest daily low and then the 100-day average zone should trigger a review of both the chart and the operating thesis. |
NTRA AI trading strategy
The NTRA AI trading strategy is a rules-based framework for a volatile diagnostics growth stock. It is not personal advice and should be paired with live prices, filings, payer updates, earnings releases, position sizing, and an independent review of risk.
Watch for NTRA to reclaim and hold the $280 to $288 resistance area with supportive volume, while revenue growth, gross margin, and 2026 guidance remain intact.
A sustained close below $270 invalidates the near-term setup. A break below $262 should prompt a broader review of technical and fundamental assumptions.
If NTRA pulls back toward $270 or the $262 to $264 moving-average zone without a change in reimbursement, clinical evidence, or guidance, compare the move with Q1 test volumes and cash-flow progress.
Do not treat every decline as a buying opportunity. A reimbursement reversal, payer dispute, adverse legal development, or weaker oncology adoption can change the setup quickly.
Track Signatera and oncology test volumes, average selling prices, gross margin, 2026 revenue guidance, net cash inflow, debt, payer concentration, cash, share count, litigation, and competitive diagnostics data.
Reduce confidence if revenue growth slows without operating leverage, if cash conversion weakens, or if the valuation remains elevated despite less favorable reimbursement or competitive evidence.
Investment research summary
Natera converts cell-free DNA and molecular-data capabilities into recurring diagnostic-test revenue by helping clinicians screen, monitor, and guide care across oncology, organ health, and women’s health.
The moat is built from clinical evidence, proprietary assays and bioinformatics, laboratory execution, physician workflow integration, payer evidence, and a growing data set. It weakens if rivals offer better evidence, access, turnaround time, or economics.
The thesis fails if coverage or pricing deteriorates, Signatera adoption disappoints, competitors win clinicians or payers, legal outcomes consume resources, growth spending prevents profitability, or dilution continues.
Management has scaled revenue and test volumes while raising 2026 guidance. The key capital-allocation question is whether commercial and clinical investment translates into durable margins and lower dependence on share issuance.
Molecular diagnostics and liquid-biopsy monitoring can benefit from more personalized care and wider use of genomic data. The opportunity depends on clinical utility, regulatory standards, physician adoption, payer reimbursement, and competition.
NTRA trades at a premium revenue valuation despite GAAP losses. Margin of safety improves if guidance, margin expansion, and cash generation translate into durable profitability, and narrows if those operating assumptions weaken.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NTRA price | $272.82 at July 8, 2026 close | StockAnalysis market-cap snapshot | July 11, 2026 |
| Market capitalization | $39.07 billion, verified as $272.82 x 143.22 million shares | financial_rigor.py market-cap verification and StockAnalysis | July 11, 2026 |
| FY2025 revenue | $2.306113 billion, up 35.9% year over year | Natera FY2025 release, Natera 2025 Form 10-K, Macrotrends, and StockAnalysis | July 11, 2026 |
| FY2025 GAAP net loss | $208.16 million | Natera 2025 Form 10-K and StockAnalysis cross-check | July 11, 2026 |
| Q1 2026 revenue and gross margin | $696.6 million and 64.7%, up 38.8% and 160 basis points year over year | Natera Q1 2026 financial results | July 11, 2026 |
| Q1 2026 tests processed | 1,013,600 total tests, including 258,900 oncology tests | Natera Q1 2026 financial results | July 11, 2026 |
| Cash and debt at March 31, 2026 | $1.0879 billion cash, cash equivalents, and restricted cash; $80.3 million debt | Natera Q1 2026 financial results and StockAnalysis cross-check | July 11, 2026 |
| 2026 revenue guidance | $2.74 billion to $2.82 billion | Natera Q1 2026 financial results | July 11, 2026 |
This NTRA page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecast ranges are scenarios based on available data and may be wrong if financial results, reimbursement, clinical evidence, regulation, competition, litigation, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
